Expert Review of Vaccines最新文献_第3页

Advances in transmission-blocking vaccines against Plasmodium falciparum and Plasmodium vivax. 恶性疟原虫和间日疟原虫传播阻断疫苗的研究进展。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-06-18 DOI: 10.1080/14760584.2025.2517720

Mayumi Tachibana, Eizo Takashima, Motomi Torii, Yimin Wu, Jetsumon Sattabongkot, Takafumi Tsuboi

引用次数: 0

Trends in adolescent and adult vaccination in pharmacy and medical settings in the United States, 2018-2024: a database study. 2018-2024 年美国药房和医疗机构中青少年和成人疫苗接种趋势：一项数据库研究。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2024-12-22 DOI: 10.1080/14760584.2024.2441255

Yi Zheng, Dong Wang, Ya-Ting Chen, Kunal Saxena, Goran Bencina, Amanda L Eiden

{"title":"Trends in adolescent and adult vaccination in pharmacy and medical settings in the United States, 2018-2024: a database study.","authors":"Yi Zheng, Dong Wang, Ya-Ting Chen, Kunal Saxena, Goran Bencina, Amanda L Eiden","doi":"10.1080/14760584.2024.2441255","DOIUrl":"10.1080/14760584.2024.2441255","url":null,"abstract":"Background: Pharmacies can increase access to vaccines. This study aimed to describe trends in the proportion of adolescent and adult vaccinations administered in pharmacies in the United States from 2018 to 2024.Research design and methods: This was a retrospective cross-sectional analysis of medical and pharmacy claims from commercial health insurance enrollees. We recorded vaccinations received by enrollees ≥9 years of age from 2018 to 2023 (routine vaccines) or 2024 (seasonal vaccines). We calculated the annual proportion of vaccinations occurring in pharmacies and the accumulated percent change in vaccination rate during each year from 2020 onward compared to 2018-2019.Results: The proportion of routine vaccinations occurring in pharmacies was higher among adults than among adolescents. For most routine vaccines, this proportion increased during the study period. The lowest proportion was observed for adolescent human papillomavirus vaccination in 2018 (0.2%), and the highest for herpes zoster vaccination among adults ≥65 years of age in 2023 (88.6%). For all age groups, pharmacy-based vaccination was more common for seasonal influenza and SARS-CoV-2 vaccines than for all routine vaccines except herpes zoster.Conclusions: Pharmacy-based vaccination is increasingly common in the United States, particularly among adults and for seasonal vaccines, and can help increase the overall level of vaccine uptake.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"53-66"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142828180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The impact of non-pharmacological interventions on nasopharyngeal Staphylococcus aureus, Streptococcus pneumoniae, Moraxella catarrhalis, Haemophilus influenzae carriage and the change of pneumococcal vaccination in healthy children under 5 years old in Beijing, China. 非药物干预对北京地区5岁以下健康儿童鼻咽金黄色葡萄球菌、肺炎链球菌、卡他莫拉菌、流感嗜血杆菌携带及肺炎球菌疫苗接种变化的影响

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-03-13 DOI: 10.1080/14760584.2025.2476521

Qianqian Du, Zhaoqiu Liu, Wei Shi, Xijie Liu, Qinghong Meng, Dongyi Zheng, Kaihu Yao

{"title":"The impact of non-pharmacological interventions on nasopharyngeal Staphylococcus aureus, Streptococcus pneumoniae, Moraxella catarrhalis, Haemophilus influenzae carriage and the change of pneumococcal vaccination in healthy children under 5 years old in Beijing, China.","authors":"Qianqian Du, Zhaoqiu Liu, Wei Shi, Xijie Liu, Qinghong Meng, Dongyi Zheng, Kaihu Yao","doi":"10.1080/14760584.2025.2476521","DOIUrl":"10.1080/14760584.2025.2476521","url":null,"abstract":"Background: We analyzed the impact of non-pharmacological interventions (NPIs) and PCV13 inoculation on nasopharyngeal (NP) carriage of Staphylococcus aureus (Sa), Streptococcus pneumoniae (Sp), Moraxella catarrhalis (Mc), and Haemophilus influenzae (Hi) in healthy children under 5-years-old in Beijing, China.Research design and methods: NP swabs were taken from healthy children seeking routine well-child care at the pediatric preventive health clinic. NP swabs were frozen in Tryptic Soy Broth (TSB) medium and stored at -80°C, and bacterial was detected by culture.Results: From December 2019 to November 2021, 1939 children were enrolled, among whom 278 (14.3%) were found to carry Sa isolates, 115 (5.9%) Sp, 39 (2.0%) Mc, and 6 (0.3%) Hi. The carriage of Sa was highest in infants under 6 months, negatively correlated with Sp and Mc. The Sa carriage rate in infants below 6 months of age rose from 26.7% in pre-NPIs to 32.7% in post-NPIs early. The 13-valent pneumococcal conjugate vaccine (PCV13) uptake rose from 42.3% in December 2019 to 62.3% by October 2021.Conclusions: The broad application of NPIs caused a decline in Sp and Mc carriage among children under 5-years-old, accompanied by an elevation in the Sa carriage rate among infants.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"206-211"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143566541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Modeling the potential public health and economic impact of COVID-19 vaccination strategies using an adapted vaccine in Peru. 在秘鲁对使用适应疫苗的COVID-19疫苗接种策略的潜在公共卫生和经济影响进行建模。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-05-17 DOI: 10.1080/14760584.2025.2505091

Carlos Fernando Mendoza, Rafael Bolanos, Marianella Perata, Moe H Kyaw, Iustina Chirila, Ben Yarnoff

{"title":"Modeling the potential public health and economic impact of COVID-19 vaccination strategies using an adapted vaccine in Peru.","authors":"Carlos Fernando Mendoza, Rafael Bolanos, Marianella Perata, Moe H Kyaw, Iustina Chirila, Ben Yarnoff","doi":"10.1080/14760584.2025.2505091","DOIUrl":"10.1080/14760584.2025.2505091","url":null,"abstract":"Background: This study evaluated the impact of various vaccination strategies using an adapted vaccine in Peru.Research design and methods: Using a previously published combined Markov-decision-tree model adapted for Peru, this study estimated the outcomes of different vaccination strategies targeting various age and risk groups. The model used age-specific epidemiology, clinical, cost, and quality-of-life inputs derived from the published literature and national surveillance data. Sensitivity analyses were conducted to assess uncertainty.Results: The vaccination strategy targeting older adults aged ≥ 60 years and the high-risk population between 12 and 59 years old with a 24% vaccine uptake was estimated to prevent 78,483 symptomatic cases, 2,962 hospitalizations, 103 deaths, and 2,913 lost QALYs compared with no vaccination, translating to an incremental decrease of $12,856,654 in total direct costs and an incremental decrease of $35,090,748 in total societal costs. These gains were further increased by expanding vaccination to additional age groups and increasing vaccine uptake.Conclusions: Vaccination in the population aged ≥ 60 years and the high-risk population between 12 and 59 years old in Peru was projected to yield substantial health and economic benefits. The impact could be substantially increased by expanding eligibility to younger age groups and increasing vaccine uptake.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"384-392"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143965300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Subolesin: a 20-year path from discovery to an effective tick vaccine. 素：从发现到有效蜱虫疫苗的20年历程。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-05-19 DOI: 10.1080/14760584.2025.2508518

José de la Fuente, Consuelo Almazán, Katherine M Kocan

引用次数: 0

Application of reverse cumulative distribution curve and scaled logit model in determining optimal immunogenic dose and prediction of protection of EV71 vaccines. 反向累积分布曲线和比例logit模型在EV71疫苗最佳免疫原剂量确定和保护预测中的应用。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2024-12-18 DOI: 10.1080/14760584.2024.2438760

Lairun Jin, Pengfei Jin, Xuefeng Zhang, Fengcai Zhu, Jingxin Li

{"title":"Application of reverse cumulative distribution curve and scaled logit model in determining optimal immunogenic dose and prediction of protection of EV71 vaccines.","authors":"Lairun Jin, Pengfei Jin, Xuefeng Zhang, Fengcai Zhu, Jingxin Li","doi":"10.1080/14760584.2024.2438760","DOIUrl":"10.1080/14760584.2024.2438760","url":null,"abstract":"Background: This study proposes the reverse cumulative distribution curve (RCDC) for optimal dose selection and a scaled logit model for estimating protection in EV71 vaccine development.Research design and methods: Data were from a phase 2 trial involving infants and young children randomized to receive either 640 U with or without adjuvant, 320 U with adjuvant, 160 U with adjuvant EV71 vaccines, or placebo. RCDCs were constructed using neutralizing antibody titers 28 days post-vaccination. Robustness of RCDC parameters was assessed via coefficient of variation for the area under the curve (AUC), the relative optimal point, median on the curve, and antibody titer of the point of maximum curvature, with geometric mean titer (GMT) as control. The scaled logit model estimated protection against EV71-associated disease for the selected optimal dose.Results: The AUC and relative optimal point demonstrated greater robustness than GMT. The 640 U with adjuvant dose had the highest AUC (0.64, 95% CI: 0.61-0.66), sum of coordinates of the relative optimal point (1.40, 95% CI: 1.34-1.43), and the highest estimated protection (93.36%, 95% CI: 79.91-97.86).Conclusions: AUC and relative optimal point of RCDC are effective for early vaccine dose screening, with protection estimated by the scaled logit model.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"37-44"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Economic evaluation of childhood pneumococcal conjugate vaccination programs in Qinghai and Hainan provinces, China. 中国青海省和海南省儿童肺炎球菌结合疫苗接种计划的经济评价。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2024-12-24 DOI: 10.1080/14760584.2024.2443223

Haonan Zhang, Chaofan Wang, Haijun Zhang, Brian Wahl, Maria Deloria Knoll, Xiaozhen Lai, Hai Fang

{"title":"Economic evaluation of childhood pneumococcal conjugate vaccination programs in Qinghai and Hainan provinces, China.","authors":"Haonan Zhang, Chaofan Wang, Haijun Zhang, Brian Wahl, Maria Deloria Knoll, Xiaozhen Lai, Hai Fang","doi":"10.1080/14760584.2024.2443223","DOIUrl":"10.1080/14760584.2024.2443223","url":null,"abstract":"Background: The burden of pneumococcal disease varies regionally in China, disproportionately affecting children in many provinces such as Qinghai and Hainan. Nevertheless, the absence of a pneumococcal conjugate vaccine (PCV) in the National Immunization Program (NIP) or local programs presents limited coverage. This study evaluated the health and economic impact of including PCV in immunization programs in Qinghai and Hainan.Research design and methods: A decision tree Markov model was constructed to simulate health outcomes and lifetime costs among children under different 13-valent PCV (PCV13) vaccination strategies compared to current practices, from societal and healthcare perspectives. Data on epidemiology, vaccine efficacy, cost, and utility were obtained from the literature and open databases. Sensitivity analyses were conducted to explore parameter uncertainty.Results: Including three-dose PCV13 in provincial programs at NIP coverage (98.91%) could avert 7100 episodes and 118 deaths in Qinghai, and 6200 episodes and 66 deaths in Hainan. It was cost-effective at the $68.2/dose in private market and cost-saving at the United Nations Children's Fund (UNICEF) recommended $25/dose for both provinces. Increasing coverage to 50% or 75% was also cost-effective. Sensitivity analyses confirmed the robustness of the results despite parameter uncertainty.Conclusions: Prioritizing PCV13 in immunization programs in Qinghai and Hainan could effectively reduce disease burden, improve population health, and promote health equity.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"67-80"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142834496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Vaccination strategies for solid organ transplant candidates and recipients: insights and recommendations. 实体器官移植候选人和接受者的疫苗接种策略：见解和建议。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-04-12 DOI: 10.1080/14760584.2025.2489659

Christopher Radcliffe, Camille N Kotton

{"title":"Vaccination strategies for solid organ transplant candidates and recipients: insights and recommendations.","authors":"Christopher Radcliffe, Camille N Kotton","doi":"10.1080/14760584.2025.2489659","DOIUrl":"10.1080/14760584.2025.2489659","url":null,"abstract":"Introduction: Vaccines save lives. They are integral to reducing the morbidity and mortality of vaccine-preventable infections in solid organ transplant recipients. Pre-transplant vaccination provides a unique opportunity for administration of live, viral vaccines, and enhanced vaccine efficacy, compared to the post-transplant period with decreased vaccine response due to immunosuppression.Areas covered: We discuss a general approach to pre- and post-transplant vaccination in solid organ transplant candidates and recipients. We then review guideline statements and recent literature related to individual vaccines, including the recently developed respiratory syncytial virus vaccine. Travel and occupation-related vaccines are also discussed.Expert opinion: The challenge of vaccination for immunocompromised patients expands as the prevalence of immunocompromised adults rises, and immunocompromised patients are frequently excluded from vaccine trials. In an age of vaccine hesitancy and reemerging vaccine-preventable infections, well-powered, prospective studies are needed to evaluate the clinical effectiveness of vaccines in solid organ transplant candidates and recipients.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"313-323"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143779590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

TAK-003: development of a tetravalent dengue vaccine. TAK-003：研制四价登革热疫苗。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-04-25 DOI: 10.1080/14760584.2025.2490295

Xavier Sáez-Llorens, Rodrigo DeAntonio, Jenny Guek Hong Low, Pope Kosalaraksa, Hansi Dean, Mayuri Sharma, Vianney Tricou, Shibadas Biswal

{"title":"TAK-003: development of a tetravalent dengue vaccine.","authors":"Xavier Sáez-Llorens, Rodrigo DeAntonio, Jenny Guek Hong Low, Pope Kosalaraksa, Hansi Dean, Mayuri Sharma, Vianney Tricou, Shibadas Biswal","doi":"10.1080/14760584.2025.2490295","DOIUrl":"https://doi.org/10.1080/14760584.2025.2490295","url":null,"abstract":"Introduction: Dengue incidence has increased over the past few decades. One tetravalent dengue vaccine based on a yellow fever backbone has been approved, but due to increased risk of severe disease in dengue-naïve recipients, its use is limited to individuals with prior dengue exposure.Areas covered: We summarize the clinical development of TAK-003, a tetravalent dengue vaccine based on a live-attenuated DENV-2 backbone. We discuss vaccine development and preclinical and clinical work leading to a commercially available formulation. TAK-003 is approved in several countries and the WHO-SAGE recommend TAK-003 to be considered for public programs in high transmission areas for individuals aged 6-16 years. Finally, we discuss the potential role of TAK-003 as part of an integrated multimodal strategy for dengue prevention.Expert opinion: TAK-003 has been assessed in a comprehensive clinical development program; demonstrating sustained efficacy and safety against all four serotypes in baseline seropositive individuals, and against DENV-1 and DENV-2 in seronegative individuals, and has been well tolerated. Effectiveness in a real world setting and safety will be monitored in ongoing and future studies, particularly for DENV-3 and DENV-4, together with the impact of a booster dose. Overall, TAK-003 shows promise as a new tool for dengue prevention.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":"24 1","pages":"324-338"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144005456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Protection and waning of vaccine-induced, natural and hybrid immunity to SARS-CoV-2 in Hong Kong. 香港SARS-CoV-2疫苗诱导、自然和混合免疫的保护和减弱。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-03-30 DOI: 10.1080/14760584.2025.2485252

Jialiang Jiang, Kwok Fai Lam, Eric Ho Yin Lau, Guosheng Yin, Yun Lin, Benjamin John Cowling

{"title":"Protection and waning of vaccine-induced, natural and hybrid immunity to SARS-CoV-2 in Hong Kong.","authors":"Jialiang Jiang, Kwok Fai Lam, Eric Ho Yin Lau, Guosheng Yin, Yun Lin, Benjamin John Cowling","doi":"10.1080/14760584.2025.2485252","DOIUrl":"10.1080/14760584.2025.2485252","url":null,"abstract":"Background: As the COVID-19 pandemic transitions into its fourth year, understanding the dynamics of immunity is critical for implementing effective public health measures. This study examines vaccine-induced, natural, and hybrid immunity to SARS-CoV-2 in Hong Kong, focusing on their protective effectiveness and waning characteristics against infection during the Omicron BA.1/2 dominant period.Research design and methods: We conducted a territory-wide retrospective cohort study using vaccination and infection records from the Hong Kong Department of Health. The analysis included over 6.5 million adults, applying the Andersen-Gill model to estimate protective effectiveness while addressing selection bias through inverse probability weighting.Results: Vaccine-induced immunity peaked one month after the first dose but waned rapidly, while boosters significantly prolonged protection. Infection-induced immunity showed higher initial effectiveness but declined faster than vaccine-induced immunity. Hybrid immunity provided the most durable protection. mRNA vaccines (Comirnaty) demonstrated greater effectiveness and slower waning compared to inactivated vaccines (CoronaVac).Conclusions: Hybrid immunity represents the most effective strategy for sustained protection against SARS-CoV-2. Public health policies should emphasize booster campaigns and hybrid immunity pathways to enhance population-level immunity and guide future COVID-19 management in Hong Kong.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"252-260"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0